Fig. 3

Dual blockade of TIGIT and LAG3 promotes proliferation of CD4⁺ and CD8⁺ T cells. A Percentages of Ki67⁺CD4⁺ and Ki67⁺CD8⁺ T cells in the primary tumors. B Percentages of Ki67⁺CD4⁺ and Ki67⁺CD8⁺ T cells in the secondary tumors. C Percentages of Ki67⁺CD4⁺ and Ki67⁺CD8⁺ T cells in the blood. The mice (n = 5) were treated with various combination therapies, including XRT + αPD1, NBTXR3 + XRT + αPD1, NBTXR3 + XRT + αPD1 + αLAG3, NBTXR3 + XRT + αPD1 + αTIGIT, and NBTXR3 + XRT + PLT as indicated in Fig. 1 A and were sacrificed on day 21. The mice which were inoculated with tumors only served as control. Immune cells from primary tumors, secondary tumors, and blood were processed and stained with αCD45-APC-Cy7, αCD3-PE-Cy7, αCD4-alexa 700, αCD8-PercpCy5.5, and αKi67-alexa 647. The cells were run with a Gallios Flow Cytometer (Beckman Coulter) and analyzed with Kaluza software Version 2.1. The data were expressed as mean ± SEM and were analyzed with a two-tailed t test. P < 0.05 was considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001